Solid Lipid Nanoparticles: Fundamentals, Design and Applications
Chapter 3 - Physicochemical Properties of Solid Lipid Nanoparticles
K. Umasankar, T. S. Saraswathi
Abstract:
Solid Lipid Nanoparticles (SLNs) are characterized by various physicochemical properties that influence their behavior and effectiveness, particularly in drug delivery and other applications. Characteristics such as encapsulation efficiency, surface morphology, zeta potential, crystallinity, and particle size and dispersion are included in this list. Some parameters, such the lipid content and the techniques of manufacture, impact the stability and drug release profile of SLNs. Ideal SLN formulations to address therapeutic demands can only be achieved by a thorough comprehension of these characteristics. In terms of stability, bioavailability, and targeted medication administration, SLN size is a critical performance component. Morphology of SLNs is often studied using microscopy methods like Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM). Importantly, zeta potential shows how charged the surface of SLNs is. A greater zeta potential is associated with better stability in SLNs because electrostatic repulsion between particles makes clumping less likely. A SLN’s crystallinity, or the organized organization of its lipids, may have a major impact on the drug release characteristics and physical stability of the nanoparticle. When testing for crystallinity in SLNs, one frequent method is differential scanning calorimetry (DSC). It is crucial that SLN formulations be stable in order to guarantee their effectiveness and safety during storage and use. Lipid composition, surfactant type, and environmental conditions (e.g., temperature, humidity) all affect SLN stability.
Keywords:
Solid Lipid Nanoparticles, Physiochemical Properties, Characterization of SLNs, Particle Size and Size Distribution, Surface Morphology, Zeta Potential and Crystallinity.
References:
[1] Uner M. Characterization and imaging of solid lipid nanoparticles and nanostructured lipid carriers. In: Aliofkhazraei M, editor. Handbook of Nanoparticles. Cham: Springer International Publishing; 2016. pp. 117-141
[2] Campos JR, Severino P, Santini A, Silva AM, Shegokar R, Souto SB, et al. Chapter 1 – Solid lipid nanoparticles (SLN): Prediction of toxicity, metabolism, fate and physicochemical properties. In: Shegokar R, editor. Nanopharmaceuticals. Elsevier; 2020. pp. 1-15. ISBN: 9780128177785. DOI: 10.1016/B978-0-12-817778-5.00001-4
[3] Danaei M, Dehghankhold M, Ataei S, HasanzadehDavarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10(57):17
[4] Jain AK, Thareja S. In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery. Artificial Cells, Nanomedicine, and Biotechnology. 2019;47(1):524-539
[5] Langevin D, Raspaud E, Mariot S, Knyazev A, Stocco A, Salonen A, et al. Towards reproducible measurement of nanoparticle size using dynamic light scattering: Important controls and considerations. NanoImpact. 2018;10:161-167
[6] Kathe N, Henriksen B, Chauhan H. Physicochemical characterization techniques for solid lipid nanoparticles: Principles and limitations. Drug Development and Industrial Pharmacy. 2014;40(12):1565-1575
[7] Andonova V, Peneva P. Characterization methods for solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). Current pharmaceutical design. 2017;23(43):6630-6642
[8] Manaia EB, Abuçafy MP, Chiari-Andréo BG, Silva BL, Oshiro Junior JA, Chiavacci LA. Physicochemical characterization of drug nanocarriers. International Journal of Nanomedicine. 2017;12:4991-5011
[9] Yousefi M, Ehsani A, Jafari SM. Lipid-based nano delivery of antimicrobials to control food-borne bacteria. Advances in Colloid and Interface Science. 2019;270:263-277
[10] Gordillo-Galeano A, Mora-Huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release. European Journal of Pharmaceutics and Biopharmaceutics. 2018;133:285-308
[11] Deshpande A, Mohamed M, Daftardar SB, Patel M, Boddu SHS, Nesamony J. Solid lipid nanoparticles in drug delivery: Opportunities and challenges. In: Mitra AK, Cholkar K, Mandal A, editors. Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices. Boston: Elsevier; 2017. pp. 291-330
[12] Omwoyo WN, Ogutu B, Oloo F, Swai H, Kalombo L, Melariri P, et al. Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles. International Journal of Nanomedicine. 2014;9:3865
[13] Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomedicine & Pharmacotherapy. 2018;103:598-613
[14] Pauw BR, Kastner C, Thunemann AF. Nanoparticle size distribution quantification: Results of a small-angle X-ray scattering inter-laboratory comparison. Journal of Applied Crystallography. 2017;50(5):1280-1288
[15] Kumar R. Chapter 8 – Lipid-based nanoparticles for drug-delivery systems. In: Mohapatra SS, Ranjan S, Dasgupta N, Mishra RK, Thomas S, editors. Micro and Nano Technologies, Nanocarriers for Drug Delivery. Elsevier; 2019. pp. 249-284. ISBN: 9780128140338. DOI: 10.1016/B978-0-12-814033-8.00008-4
[16] Lin P-C, Lin S, Wang PC, Sridhar R. Techniques for physicochemical characterization of nanomaterials. Biotechnology Advances. 2014;32(4):711-726
[17] Singer A, Barakat Z, Mohapatra S, Mohapatra SS. Chapter 13 – Nanoscale drug-delivery systems: In vitro and in vivo characterization. In: Mohapatra SS, Ranjan S, Dasgupta N, Mishra RK, Thomas S, editors. Micro and Nano Technologies, Nanocarriers for Drug Delivery. Elsevier; 2019. pp. 395-419. ISBN: 9780128140338. DOI: 10.1016/B978-0-12-814033-8.00013-8
[18] Liu D, Jiang S, Shen H, Qin S, Liu J, Zhang Q, Li R, Xu Q. Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method. J. Nanoparticle Res. 2011, 13, 2375–2386.
[19] Wang T, Wang N, Zhang Y, Shen W, Gao X, Li T. Solvent injection-lyophilization of tert-butyl alcohol/water cosolvent systems for the preparation of drug-loaded solid lipid nanoparticles. Colloids Surf. B Biointerfaces 2010, 79, 254–261.
[20] Duong VA, Nguyen TTL, Maeng HJ. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules 2020, 25, 4781.
[21] Lingling G, Yuan Z, Weigen L. Preparation, optimization, characterization and in vivo pharmacokinetic study of asiatic acid tromethamine salt-loaded solid lipid nanoparticles. Drug Dev. Ind. Pharm. 2016, 42, 1325–1333.
[22] Kanwar R, Gradzielski M, Mehta SK. Biomimetic Solid lipid nanoparticles of sophorolipids designed for antileprosy drugs. J. Phys. Chem. B 2018, 122, 6837–6845.
[23] Hansraj GP, Singh SK. Kumar P. Sumatriptan succinate loaded chitosan solid lipid nanoparticles for enhanced anti-migraine potential. Int. J. Biol. Macromol. 2015, 81, 467–476.
[24] Shafique H, Ahad A, Khan W, Want MY, Bhatt PC, Ahmad S, Panda BP, Mujeeb M. Ganoderic acid -loaded solid lipid nanoparticles ameliorate d-galactosamine induced hepatotoxicity in Wistar rats. J. Drug Deliv. Sci. Technol. 2019, 50, 48–56.
[25] Duong VA, Nguyen TTL, Maeng HJ, Chi SC. Preparation of ondansetron hydrochloride-loaded nanostructured lipid carriers using solvent injection method for enhancement of pharmacokinetic properties. Pharm. Res. 2019, 36, 138.
[26] Singh A, Ahmad I, Akhter S, Jain GK, Iqbal Z, Talegaonkar S, Ahmad FJ. Nanocarrier based formulation of Thymoquinone improves oral delivery: Stability assessment, in vitro and in vivo studies. Colloids Surf. B Biointerfaces 2013, 102, 822–832.
[27] Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56, 1257–1272.
[28] Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011, 12, 62–76.
[29] Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery—Drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998, 45, 149–155.
[30] Wissing SA, Müller RH. Solid lipid nanoparticles as carrier for sunscreens: In vitro release and in vivo skin penetration. J. Control. Release 2002, 81, 225–233.
[31] Jain S, Jain S, Khare P, Gulbake A, Bansal D, Jain SK. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Deliv. 2010, 17, 443–451.
[32] Castelli F, Puglia C, Sarpietro MG, Rizza L, Bonina F. Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int. J. Pharm. 2005, 304, 231–238.
[33] Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54, S131–S155.
[34] Freitas C, Müller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int. J. Pharm. 1998, 168, 221–229.
[35] Degobert G, Aydin D. Lyophilization of nanocapsules: Instability sources, formulation and process parameters. Pharmaceutics 2021, 13, 1112.
[36] Satari N, Taymouri S, Varshosaz J, Rostami M, Mirian M. Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy. Drug Dev. Ind. Pharm. 2020, 46, 1265–1277.
[37] Nguyen TTL, Duong VA, Maeng HJ, Chi SC. Development of an oil suspension containing granisetron hydrochloride as a sustained-release parenteral formulation for enhancement of pharmacokinetic properties. J. Drug Deliv. Sci. Technol. 2019, 51, 643–650.
[38] Nguyen TTL, Duong VA, Maeng HJ, Chi SC. Preparation of an oil suspension containing ondansetron hydrochloride as a sustained release parenteral formulation. Drug Deliv. Transl. Res. 2019, 10, 282–295.